Lurasidone: In the treatment of schizophrenia

CNS Drugs

Volumn 27, Issue 1, 2013, Pages 67-80

  Sanford, Mark ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; CHOLESTEROL; CLOZAPINE; CYTOCHROME P450 3A4; DIGOXIN; DILTIAZEM; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; GLUCOSE; HALOPERIDOL; KETOCONAZOLE; LITHIUM; LORAZEPAM; LURASIDONE; MIDAZOLAM; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PLACEBO; QUETIAPINE; RIFAMPICIN; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR; TEMAZEPAM; TRIACYLGLYCEROL; ZIPRASIDONE; ZOLPIDEM;

AGITATION; AKATHISIA; ANOREXIA; ANXIETY; ANXIETY DISORDER; AREA UNDER THE CURVE; BACKACHE; BINDING AFFINITY; BRIEF PSYCHIATRIC RATING SCALE; COGNITION; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; GROUPS BY AGE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPERTENSION; INSOMNIA; LIVER DYSFUNCTION; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; METABOLIC PARAMETERS; MULTICENTER STUDY (TOPIC); NAUSEA; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECEPTOR OCCUPANCY; RECOMMENDED DRUG DOSE; RELAPSE; RESTLESSNESS; REVIEW; SALIVATION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TACHYCARDIA; VOMITING; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISOINDOLES; SCHIZOPHRENIA; THIAZOLES; TIME FACTORS;

EID: 84873029316     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0026-x     Document Type: Review

References (31)

1. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635-45.
2. Kane JM, Correll CU. Past and present progress in the pharmacological treatment of schizophrenia. J Clin Psychiatry. 2010;71(9):1115-24.
3. Jindal RD, Keshavan MS. Classifying antipsychotic agents: need for new terminology. CNS Drugs. 2008;22(12):1047-59.
4. Hopkins CR. ACS chemical neuroscience molecule spotlight on Latuda (lurasidone; SM-13,496). ACS Chem Neurosci. 2011;2(2):58-9.
5. Sunovion Pharmaceuticals Inc. Latuda (lurasidone hydrochloride) tablets, for oral use: US prescribing information. 2012. http://latuda.com/ LatudaPrescribingInformation.pdf. Accessed 2012 Sep 12.
6. 1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171-81.
7. Fumagalli F, Calabrese F, Luoni A, et al. Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int J Neuropsychopharmcol. 2012;15(2):235-46.
8. Yuen EY, Li X, Wei J, et al. The novel antipsychotic drug lurasidone enhances N-methyl-d-aspartate receptor-mediated synaptic responses. Mol Pharmacol. 2012;81(2):113-9.
9. Enomoto T, Ishibashi T, Tokuda K, et al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res. 2008;186(2):197-207.
10. Enomoto T. Effects of the novel antipsychotic lurasidone on prefrontal cognitive functioning in rats [abstract no. 646.24/V36]. 39th Annual Meeting of the Society for Neuroscience, Chicago, IL; 2009.
11. Ikeda K, Fukuoka T, Ikejiri M, et al. Cognitive enhancing effects of lurasidone in non-human primates: object retrieval with detours, a test of executive function [abstract]. Int J Neuropsychopharmcol. 2010;13:94-5.
12. Horiguchi M, Hannaway KE, Adelekun AE, et al. Subchronic treatment with lurasidone has both preventive and enduring reversal effects on the phencyclidine (PCP)-induced deficit in novel object recognition (NOR) in rats [abstract]. Neuropsychopharmacology. 2011;36:S436.
13. Potkin SG, Keator DB, Preda A, et al. D2 receptor occupancy measured with 18F-fallypride following lurasidone treatment in schizophrenia patients [abstract]. Neuropsychopharmacology. 2011;36:S173.
14. Harvey PD, Murasaki M, Cucchiaro J, et al. A three arm dose finding study of lurasidone: efficacy and tolerability data [abstract]. Schizophr Res. 2010;117(2-3):374-5.
15. Chiu Y, Gu K, Poola N, et al. Effect of hepatic impairment on the pharmacokinetics of lurasidone [abstract]. Clin Pharmacol Ther. 2011;89:S32.
16. Preskorn S, Chiu YY, Sarubbi D, et al. Lurasidone pharmacokinetics: assessment of potential for drug-drug interactions [abstract]. Neuropsychopharmacology. 2010;35:S395.
17. Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week placebo-controlled study. Psychopharmacology (Berl). 2012 February 19 (Epub).
18. Centre for Drug Evaluation and Research. Medical review lurasidone 2010. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/200603Orig1s000MedR.pdf. Accessed 2012 Sep 12.
19. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829-36.
20. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957-67.
21. Loebel A, Cucchiaro J, Pikalov A, et al. Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled, 6-week, pearl 3 trial [abstract]. Neuropsychopharmacology. 2010;35:S313-4.
22. Dainippon Sumitomo Pharma Co Ltd. Dainippon Sumitomo Pharma announces Pan-Asia study results for lurasidone, an atypical antipsychotic agent, in the treatment of schizophrenia [media release]. 2011. http://www.ds-pharma.com.
23. Pikalov A, Cucchiaro J, Sarma K, et al. Lurasidone in the acute treatment of schizophrenia: results of the double-blind placebo- and quetiapine XR-controlled 6-week study of lurasidone in adult patients with schizophrenia [abstract no. 225]. Poster presented at the 26th Annual US Psychiatric and Mental Health Congress. 2011 Nov 7-10, Las Vegas, NEV.
24. Stahl S, Cucchiaro J, Simonelli D, et al. Long-term safety and tolerability of lurasidone in subjects with schizophrenia: results of a 6-month, open-label study [abstract]. Neuropsychopharmacology. 2010;35:S316-7.
25. Loebel A, Cucchiaro J, Xu J, et al. Relapse prevention with lurasidone vs. quetiapine XR in chronic schizophrenia: results of a 12-month, double-blind study. Neuropsychopharmacology. 2011;36:S101.
26. Harvey PD, Ogasa M, Cucchiaro J, et al. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res. 2011;127(1-3):188-94.
27. Citrome L. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clin Schizophr Relat Psychoses. 2012;6(2):76-85.
28. Harvey P, Cucchiaro J, Pikalov A, et al. Cognitive performance in patients with schizophrenia treated with lurasidone: results from a placebo- and active-controlled acute phase study followed by a 6 month double-blind extension [abstract]. Neuropsychopharmacology. 2011;36:S169-70.
29. Newcomer JW, Siu C, Pikalov A, et al. Impact of lurasidone and olanzapine on framingham 10-year coronary heart disease risk estimate in schizophrenia [abstract]. Schizophr Bull. 2011;37:316.
30. Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27(3):165-76.
31. Sunovien. PEARL Schizophrenia Maintenance study (NCT01435928) [online]. http://clinicaltrials.gov/ct2/show/NCT01435928. Accessed Oct 9 2012.